maintain weight after semaglutide 💉 GLP-1 medications are changing obesity treatment—but are they enough? and tirzepatide have revolutionized management and diabetes care by helping patients lose weight and improve blood sugar control. But sustainable Woman shares journey of weight

The FDA action date to decide on the Wegovy oral formulation NDA is in the fourth quarter of 2025

& Bartolom, A

Side Effects by the Numbers Nausea How common ~40% Typical duration Peaks within 1 hr, eases over 2-3 hr Flushing How common ~20% Typical duration Transient, under a few hours Injection-site reaction How common ~13% Typical duration Minor, fades same day Headache How common ~11% Typical duration Transient, hours Vomiting How common ~5% Typical duration Early, short-lived Blood-pressure rise How common ~+6/+3 mmHg avg Typical duration Resolves in ~8-12 hr Skin/gum darkening How common ~1% Typical duration Builds with use, may persist Kingsberg SA et al., "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder" (RECONNECT Phase III trials), Obstet Gynecol, 2019

Lawson JS, Syme HM, Wheeler-Jones CP, Elliott J